3-(Trifluoromethoxy)benzoic acid → (2Z)-2-(3-butyl-5-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-1-[3-(trifluoromethoxy)phenyl]ethanone

HRID 448049

Reaktionsgleichung

Reaktionsgleichung von HRID 448049
[F:1][C:2]([F:14])([F:13])[O:3][C:4]1[CH:5]=[C:6]([CH:10]=[CH:11][CH:12]=1)[C:7]([OH:9])=O.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C.[I-].[CH2:49]([N+:53]1[N:57]=[C:56]([CH3:58])[S:55][C:54]=1[CH3:59])[CH2:50][CH2:51][CH3:52]>>[CH2:49]([N:53]1[N:57]=[C:56]([CH3:58])[S:55]/[C:54]/1=[CH:59]\[C:7]([C:6]1[CH:10]=[CH:11][CH:12]=[C:4]([O:3][C:2]([F:1])([F:14])[F:13])[CH:5]=1)=[O:9])[CH2:50][CH2:51][CH3:52]

Komponenten

5

Versuchsvorschrift

In a 20 mL vial 3-(trifluoromethoxy)benzoic acid (0.9 mL of 0.2 M in DMA, 1.10 equiv) was added followed by the addition of HATU (76 mg in 0.7 mL of DMA, 0.2 mmol, 1.20 equiv.), DIEA (51 mg in 0.7 mL of DMA, 0.4 mmol, 2.40 equiv.), and finally 3-butyl-2,5-dimethyl-1,3,4-thiadiazol-3-ium iodide (49 mg in 0.7 mL of DMA, 0.17 mmol, 1 equiv.). The mixture was shaken overnight at room temperature and then concentrated in vacuo. The resulting residue was taken up in 1:1 DMSO/MeOH and purified by reverse phase HPLC using a method analogous to that described in Example 53 to provide the title compound. 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm 0.90 (t, 3H) 1.27-1.42 (m, 2 H) 1.69-1.80 (m, 2 H) 2.49 (s, 3 H) 4.27 (t, 2 H) 6.78 (s, 1 H) 7.43-7.53 (m, 1 H) 7.58-7.65 (m, 1 H) 7.92 (s, 1 H) 8.03-8.11 (m, 1 H); MS (ESI) m/z 359 (M+H)+.

Aufarbeitung

  1. concentrationconcentrated in vacuo
  2. custompurified by reverse phase HPLC

Quellen und Nachweise

ORD-Eintrag
ord-aff208a78a8648fdbe77b90673cee48e
Quelldatensatz
uspto-grants-2013_07
Patentnummer
US08481574B2

Verknüpfte Notizen

Wird geladen…